Tanvex BioPharma Price To Book vs. Cash And Equivalents

6541 Stock  TWD 72.30  6.20  9.38%   
Based on the key profitability measurements obtained from Tanvex BioPharma's financial statements, Tanvex BioPharma may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess Tanvex BioPharma's ability to earn profits and add value for shareholders.
For Tanvex BioPharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Tanvex BioPharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Tanvex BioPharma utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Tanvex BioPharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Tanvex BioPharma over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities.
Please note, there is a significant difference between Tanvex BioPharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tanvex BioPharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tanvex BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Tanvex BioPharma Cash And Equivalents vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Tanvex BioPharma's current stock value. Our valuation model uses many indicators to compare Tanvex BioPharma value to that of its competitors to determine the firm's financial worth.
Tanvex BioPharma is rated fourth in price to book category among its peers. It is number one stock in cash and equivalents category among its peers creating about  231,862,063  of Cash And Equivalents per Price To Book. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tanvex BioPharma's earnings, one of the primary drivers of an investment's value.

Tanvex Cash And Equivalents vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

Tanvex BioPharma

P/B

 = 

MV Per Share

BV Per Share

 = 
7.12 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.

Tanvex BioPharma

Cash

 = 

Bank Deposits

+

Liquidities

 = 
1.65 B
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).

Tanvex Cash And Equivalents Comparison

Tanvex BioPharma is currently under evaluation in cash and equivalents category among its peers.

Tanvex BioPharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Tanvex BioPharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Tanvex BioPharma will eventually generate negative long term returns. The profitability progress is the general direction of Tanvex BioPharma's change in net profit over the period of time. It can combine multiple indicators of Tanvex BioPharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar and biologic products and drugs in Taiwan and the United States. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands. TANVEX BIOPHARMA is traded on Taiwan Stock Exchange in Taiwan.

Tanvex Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Tanvex BioPharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Tanvex BioPharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Tanvex BioPharma's important profitability drivers and their relationship over time.

Use Tanvex BioPharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tanvex BioPharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tanvex BioPharma will appreciate offsetting losses from the drop in the long position's value.

Tanvex BioPharma Pair Trading

Tanvex BioPharma Pair Trading Analysis

The ability to find closely correlated positions to Tanvex BioPharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tanvex BioPharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tanvex BioPharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tanvex BioPharma to buy it.
The correlation of Tanvex BioPharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tanvex BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tanvex BioPharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tanvex BioPharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Tanvex BioPharma position

In addition to having Tanvex BioPharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Volatility ETFs Thematic Idea Now

Volatility ETFs
Volatility ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Volatility ETFs theme has 26 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Volatility ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Tanvex Stock Analysis

When running Tanvex BioPharma's price analysis, check to measure Tanvex BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tanvex BioPharma is operating at the current time. Most of Tanvex BioPharma's value examination focuses on studying past and present price action to predict the probability of Tanvex BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tanvex BioPharma's price. Additionally, you may evaluate how the addition of Tanvex BioPharma to your portfolios can decrease your overall portfolio volatility.